LAUSR

&NA; Metastasis poses a long‐standing treatment challenge for many cancers including breast cancer. Once spreading out, cell‐selective delivery of drug appears especially critical. Here, we report on epidermal growth factor receptor and CD44 dual‐targeted hyaluronic acid nanogels (EGFR/CD44‐NGs) that afford enhanced targetability and protein therapy for metastatic 4T1 breast cancer in vivo. Flow cytometry in CD44 and EGFR‐positive 4T1 metastatic breast cancer cells showed over 6‐fold higher cellular uptake of EGFR/CD44‐NGs than mono‐targeting CD44‐NGs. MTT and scratch assays displayed that saporin‐loaded EGFR/CD44‐NGs (Sap‐EGFR/CD44‐NGs) was highly potent in inhibiting growth as well as migration of 4T1 cells in vitro, with an IC50 of 5.36 nM, which was 1.7‐fold lower than that for Sap‐CD44‐NGs. In 4T1‐luc metastatic breast cancer model in mice, Sap‐EGFR/CD44‐NGs exhibited significant inhibition of tumor metastasis to lung at a small dose of 3.33 nmol Sap equiv./kg. Increasing the dosage to 13.3 nmol Sap equiv./kg resulted in further reduced lung metastasis without causing notable adverse effects. These dual‐targeted nanogels with improved cancer cell selectivity provide a novel platform for combating breast cancer metastasis. Graphical abstract Figure. No caption available.